Product Name: Ack1 (856-862) pY859+pY860
Product Number: PE-04ACF99
Size: 200 µg      Price:71.00
1 mg      $US142.00
5 mg      311.00
Peptide Name: Ack1 (856-862) pY859+pY860

Product Use: Services as a blocking peptide for use with the ACK1-pY859+pY860 rabbit polyclonal antibody (Cat. No.: AB-PK513) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the Inhibitor_Mig-6 domain. Two of the main sites of phosphorylation of ACK1.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: STH-pY-pY-LL

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys

Peptide Modifications Other: Phosphorylated

Peptide Molecular Mass Calculated: 1230.16 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: Ack1 - pY859+pY860 phosphosite-specific antibody (Cat. No.: AB-PK513)

Scientific Background: Ack1 (TNK2) is a protein-tyrosine kinase of the TK group and Ack family. It appears to be a tumour suppressor protein (TSP). Cancer-related mutations in Ack1 in human tumours point to a loss of function of the protein kinase. The active form of the protein kinase normally acts to inhibit tumour cell proliferation. It is implicated in numerous roles, including: cell spreading and migration, cell survival, cell growth, and proliferation. TNK2 is known to phosphorylate: Akt1, AR, MCF2, WASL and WWOX. In this capacity TNK2 negatively regulates the tumour suppressor, WWOX, whilst activating the oncoproteins, Akt1 and AR. Mutations in this gene have been observed in ovarian, skin, and stomach tumours. Phosphorylation at Y284 in Ack1 increases its phosphotransferase activity. Its SH3 domain appears to play an autoinhibitory role.